The Biotechnology and Pharmaceutical Industries Group Biocubafarma announced that the first Cuban-American biotechnology company has been created: Innovative Immunotherapy Alliance SA, which will be based in the Mariel Development Special Zone (Cuba).
This new joint venture has been created among the commercial subsidiaries of two renowned research centers: the Molecular Immunology Center of Cuba and the Roswell Park Comprehensive Cancer Center (USA).
This historic step in the scientific collaboration between the two countries will allow the advancement of the research and development of new cancer drugs. The new biotechnology company will include among its products the drug CIMAVax-EGF, known therapy against lung cancer, and three additional treatments of immunotherapy for different tumors, all developed in Cuba.
In the first years, the joint company will have as main objective to develop scientific and clinical research to demonstrate the safety and effectiveness of these novel treatments. If these studies are successful, the company will be in a position to export these products.